Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
How To Build A Dividend Growth Portfolio In An Overpriced Market
The stock market as measured by the S&P is currently at an all-time high which makes it very challenging to try to build a quality dividend growth portfolio. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
These stocks dividends continue to flow and grow. 
Via The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years. 
Via The Motley Fool
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%. 
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years. 
Via The Motley Fool
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 3 Best Stocks to Buy to Survive Another S&P 500 Crash
These three stocks to buy now will protect your portfolio if the S&P 500 crashes again regardless of whether there is a recession or not. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
3 Stocks Retirees Should Absolutely Love
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Warren Buffett's Approach To Investing In Election Years
Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio consistently, regardless of elections or market conditions. 
Via Benzinga
Elliott Wave Technical Analysis: AbbVie Inc.
An in-depth look at ABBV's price movements using the Elliott Wave Theory, helping traders identify potential opportunities based on current trends and market structure. 
Via Talk Markets
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
Exposures Product Safety
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Via Benzinga
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts. 
Via The Motley Fool
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Explore top stocks to buy, leading in social media, semiconductors, entertainment, restaurants, payments and biotechnology. 
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Here are three powerhouse growth stocks long-term investors may want to hone in on during this part of the market cycle. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.